SCHEMBL2946261

SCHEMBL2946261

Nc1cc(Br)ccc1NC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
KDM4E B2RXH2 1/20 0.56
GAA P10253 1/20 0.56
AAK1 Q2M2I8 3/20 0.52
ALOX15 P16050 2/20 0.49
CHEK1 O14757 1/20 0.40
NTRK1 P04629 1/20 0.40
MET P08581 1/20 0.40
PIM1 P11309 1/20 0.40
LTK P29376 1/20 0.40
GRK5 P34947 1/20 0.40
MAP2K2 P36507 1/20 0.40
CDK8 P49336 1/20 0.40
NEK2 P51955 1/20 0.40
LIMK1 P53667 1/20 0.40
TYRO3 Q06418 1/20 0.40
MAP4K2 Q12851 1/20 0.40
DYRK1A Q13627 1/20 0.40
AURKB Q96GD4 1/20 0.40
IDO1 P14902 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23176976 0.98 MAPT (0.59) MAPTKDM4EGAAAAK1ALOX15
SCHEMBL17678063 0.96 MAPT (0.51) MAPTKDM4EGAAAAK1ALOX15
SCHEMBL29502212 0.93 AAK1 (0.48) MAPTKDM4EGAAAAK1ALOX15
SCHEMBL459719 0.93 AAK1 (0.48) MAPTKDM4EGAAAAK1ALOX15
SCHEMBL2514778 0.86 MAPT (0.56) MAPTKDM4EGAAAAK1ALOX15
SCHEMBL2687892 0.85 AAK1 (0.44) MAPTKDM4EGAAAAK1ALOX15
SCHEMBL21293969 0.85 AAK1 (0.46) MAPTKDM4EGAAAAK1ALOX15
SCHEMBL29791971 0.85 AAK1 (0.44) MAPTKDM4EGAAAAK1ALOX15
SCHEMBL20096321 0.85 AAK1 (0.46) MAPTKDM4EGAAAAK1ALOX15
SCHEMBL20096170 0.85 AAK1 (0.48) MAPTKDM4EGAAAAK1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885KDM4E 1911/4885GAA 2935/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4830/4885KDM4E 1563/4885GAA 3136/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885KDM4E 1911/4885GAA 2935/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR MAPT 4806/4885KDM4E 1143/4885GAA 2772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.